While the peptide is not a weight-loss therapy, improving gut health may support metabolic function and indirectly influence weight regulation
doi: 10.1530/EJE-07-0148
The top opportunities in the GLP-1 receptor agonist markets segmented by end users will arise in the hospitals segment, which will gain $43,597.5 million of global annual sales by 2030
Rapid weight loss can lead to various side effects, like fatigue, gastrointestinal problems, hair loss, changes in facial appearance, visible signs of premature aging, digestive issues, reduced muscle mass and bone density, and mental health issues such as depression and anxiety
Consumers must do their due diligence before taking new vitamins
Initial fatigue: Some users report tiredness during the first few days